Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
When patients present with both ESR1 and PI3K mutations, treatment selection isn't based on a definitive molecular test. Instead, oncologists make a clinical judgment, inferring the dominant resistance pathway from factors like the duration of prior therapy to guide their choice of targeted agent.
Related Insights
A key distinction for oncologists is that PIK3CA mutations are typically "truncal" (present from baseline), whereas ESR1 mutations are "acquired" after exposure to aromatase inhibitors. This biological difference dictates when and how to test for each biomarker throughout a patient's treatment journey.
Next-generation mutant-specific PI3K inhibitors could lead to complex biomarker requirements. A future drug label might require a PIK3CA mutation for eligibility but simultaneously exclude patients who also have downstream PTEN or AKT alterations, which can confer resistance.
Dr. Bardia emphasizes that ESR1 is an 'acquired alteration,' meaning the mutation can develop during treatment. This necessitates a shift from one-time diagnostic testing to a dynamic, serial testing model. Repeat testing is critical to identify these actionable mutations as they arise, allowing patients to access newly approved targeted therapies.
Clinicians currently struggle to decide between an oral SERD or a PAM inhibitor when both ESR1 and PAM pathway mutations are present. Dr. Wander frames this as a temporary problem that will be solved within five years by the arrival of combination therapies featuring next-generation versions of both drug classes, making the choice unnecessary.
Clinicians must recognize that liquid and solid biopsies show significant discordance. ESR1 mutations are more frequently detected in liquid assays, while PIK3CA mutations are more often found in solid tissue. This variability by gene directly impacts the optimal testing strategy for patients.
While PI3K pathway alterations are linked to a poor prognosis, real-world data provides reassurance for a common clinical dilemma. Patients with co-mutations in both ESR1 and PI3K pathways still achieve significant benefit from elacestrant monotherapy, with progression-free survival (5.2-6.3 months) comparable to the overall population in the pivotal EMERALD trial.
Not all mutations are equal. PIK3CA alterations are often present from the start (truncal mutations), indicating a more aggressive cancer. In contrast, ESR1 mutations are typically acquired later as a direct mechanism of resistance to endocrine therapy, making repeat testing after disease progression crucial.
Post-approval studies of the oral SERD elacestrant confirm its clinical benefit in ESR1-mutant breast cancer. However, this real-world evidence also reveals a new insight: patients who have both an ESR1 and a PIK3CA mutation tend to have a shorter time on treatment, suggesting that the PIK3CA mutation may drive resistance to this therapy.
Even with contemporaneously collected samples, biomarker concordance between solid tissue and liquid biopsies is not uniform. Data shows ESR1 mutations are consistently more likely to be discordant—often found only in liquid—than PIK3CA or AKT mutations, reinforcing the need for gene-specific testing strategies.
For patients with both ESR1 and PIK3CA mutations, emerging data suggests prioritizing an oral SERD-based combination. The EMBER-3 trial showed imlunestrant plus abemaciclib achieved a ~12-month PFS in this subgroup, starkly outperforming the ~5.6-month PFS seen with PI3K/AKT inhibitor combinations like capivasertib-fulvestrant in the CAPItello-291 trial.